AC Immune (ACIU)
(Delayed Data from NSDQ)
$3.91 USD
0.00 (0.00%)
Updated Jul 26, 2024 04:00 PM ET
Pre-Market: $3.99 +0.08 (2.05%) 9:00 AM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.91 USD
0.00 (0.00%)
Updated Jul 26, 2024 04:00 PM ET
Pre-Market: $3.99 +0.08 (2.05%) 9:00 AM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Zacks News
Top Ranked Momentum Stocks to Buy for January 30th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 30th.
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
by Kinjel Shah
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
Linde (LIN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Favorable industrial production in the United States is likely to have favored Linde's (LIN) Q3 earnings.
AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug
by Zacks Equity Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
by Kinjel Shah
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.
Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune Initiates Phase I Study for Alzheimer's Disease
by Zacks Equity Research
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
by Zacks Equity Research
Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.
Lilly (LLY) Signs New Immunology Deal With Private Biotech
by Zacks Equity Research
Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
What Makes AC Immune (ACIU) a New Buy Stock
by Zacks Equity Research
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
by Zacks Equity Research
Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.
Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
by Zacks Equity Research
An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
by Zacks Equity Research
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
What Makes AC Immune (ACIU) a New Buy Stock
by Zacks Equity Research
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AC Immune Enters Oversold Territory
by Zacks Equity Research
AC Immune SA (ACIU) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Top Ranked Momentum Stocks to Buy for January 25th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 25th:
Top Ranked Momentum Stocks to Buy for January 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
Top Ranked Momentum Stocks to Buy for January 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 22nd:
Moving Average Crossover Alert: AC Immune
by Zacks Equity Research
AC Immune SA (ACIU) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher
by Zacks Equity Research
Stemline Therapeutics (STML) shares rose nearly 10% in the last trading session, amid huge volumes.
Biogen Inks Two Deals to Make Drugs for Neurological Diseases
by Zacks Equity Research
Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.